Effect of Prolactin on Carcinoembryonic Antigen-specific Cytotoxic T Lymphocyte Response Induced by Dendritic Cells
Overview
Authors
Affiliations
The cytokine hormone prolactin (PRL) has been shown previously to modulate native cellular responses and maturation of antigen-presenting cells. Here we have addressed its effect on the antigen-specific response of cytotoxic T lymphocytes (CTL). CTL were generated from HLA-A2 lymphocytes after three rounds of stimulation with autologous dendritic cells loaded with HLA-A2-restricted carcinoembrionic antigen (CEA) Cap-1 (YLSGANLNL) peptide. Selected cultures were expanded on cytokine-supplemented feeder-layers, enriched for CD8+ lymphocytes and analysed for PRL-receptor (PRL-R) expression and PRL responsiveness. Resting CD8+ lymphocytes were negative for PRL-R, whereas antigen-activated CD8+ lymphocytes derived from long-term cultures were highly positive. Results of a 51Cr release assay showed CTL killing of CEA-loaded, but not unloaded, T2 cell line and the CEA-positive gastric carcinoma cell line KATO, but not of the CEA-negative T leukaemia cell line Jurkat. Interferon (IFN)-gamma release, evaluated in an ELISPOT assay against CEA-loaded T2, was enhanced (P < 0.05) by concentrations of PRL (12-25 ng/ml) very close to the physiological levels (6-20 ng/ml), but was decreased (P < 0.05) by high concentrations (200 ng/ml). Pre-incubation of the stimulators with the anti-MHC class I MoAb W6.32 induced a 40-60% decrease of the PRL-boosted IFN-gamma release, thus proving the MHC restriction of the lymphocyte response. Cytotoxicity against CEA-loaded T2 and KATO cell lines was also increased by 12-25 ng (P < 0.05) and decreased (P < 0.05) by 200 ng PRL. Pre-incubation of CTL with an antibody specific for the PRL-R almost completely abrogated this effect.
The effect of prolactin on immune cell subsets involved in SLE pathogenesis.
Legorreta-Haquet M, Santana-Sanchez P, Chavez-Sanchez L, Chavez-Rueda A Front Immunol. 2022; 13:1016427.
PMID: 36389803 PMC: 9650038. DOI: 10.3389/fimmu.2022.1016427.
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients.
Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni M J Transl Med. 2008; 6:25.
PMID: 18485193 PMC: 2415031. DOI: 10.1186/1479-5876-6-25.